---
title: "Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291139753.md"
description: "The FDA has implemented a rolling review process to expedite evaluations of New Drug Applications (NDAs). This allows the FDA to review completed modules of the NDA before the entire application is submitted. The aim is to streamline the review process and accelerate the approval timeline, benefitting both the FDA and the applicants. This process is particularly beneficial in cases where time is crucial, allowing for earlier feedback and potentially speeding up the overall approval process."
datetime: "2026-06-29T11:31:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291139753.md)
  - [en](https://longbridge.com/en/news/291139753.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291139753.md)
generator: "portal-rs"
---

# Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

The FDA has implemented a rolling review process to expedite evaluations of New Drug Applications (NDAs). This allows the FDA to review completed modules of the NDA before the entire application is submitted. The aim is to streamline the review process and accelerate the approval timeline, benefitting both the FDA and the applicants. This process is particularly beneficial in cases where time is crucial, allowing for earlier feedback and potentially speeding up the overall approval process.

### Related Stocks

- [PVLA.US](https://longbridge.com/en/quote/PVLA.US.md)

## Related News & Research

- [Implantica wins FDA approval for RefluxStop acid reflux device](https://longbridge.com/en/news/296536461.md)
- [Rein Therapeutics says FDA grants Fast Track status to LTI-03 in idiopathic pulmonary fibrosis](https://longbridge.com/en/news/296487342.md)
- [Oncolytics says FDA aligns on pivotal expansion path for REO 033 colorectal cancer trial](https://longbridge.com/en/news/296232477.md)
- [Protagenic gets FDA pre-IND feedback supporting planned Phase 1 trial for PT00114 in generalized anxiety disorder](https://longbridge.com/en/news/296491293.md)
- [Femasys says FDA OKs modular PMA pathway for FemBloc birth control device](https://longbridge.com/en/news/296359782.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**